by Eric Christianson | Feb 25, 2026 | Cardiovascular Medication and Disease State Clinical Pearls
When a patient presents with dizziness, falls, or orthostatic symptoms, antihypertensives and diuretics often get the blame first. However, many non–blood pressure medications can lower blood pressure through a variety of mechanisms. Failing to recognize these...
by Eric Christianson | Feb 22, 2026 | Cardiovascular Medication and Disease State Clinical Pearls
Tachycardia is a common and sometimes overlooked adverse effect in clinical practice. Whether it is due to direct sympathetic stimulation, reflex mechanisms, or reflex compensatory mechanisms, understanding the “why” behind medication-induced tachycardia can help...
by Eric Christianson | Feb 18, 2026 | Cardiovascular Medication and Disease State Clinical Pearls
Thiazide and thiazide-like diuretics remain foundational therapies in hypertension management. Two of the most commonly discussed agents are hydrochlorothiazide (HCTZ) and chlorthalidone. While they are often used interchangeably in practice, important pharmacologic...
by Eric Christianson | Feb 11, 2026 | Cardiovascular Medication and Disease State Clinical Pearls
Fibrates are lipid-lowering agents that are primarily used to reduce triglycerides. They are most beneficial in patients with significantly elevated triglyceride levels, particularly those above 500 mg/dL, where the primary clinical goal is reducing the risk of...
by Eric Christianson | Feb 4, 2026 | Cardiovascular Medication and Disease State Clinical Pearls
Rhabdomyolysis happens when muscle cells break down and release their contents into the blood. These substances can damage the kidneys and cause serious problems like kidney failure. It is often triggered by medications, injuries, extreme exercise, or drug...
by Eric Christianson | Jul 20, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
Direct oral anticoagulants (DOACs) are widely used in a variety of conditions, including atrial fibrillation, pulmonary embolism, and deep vein thrombosis. Most DOACs are metabolized by CYP3A4 and utilize the P-glycoprotein (P-gp) transporter. Thus, common...
